Healthcare - Biotechnology - NASDAQ - US
$ 1.29
-3.01 %
$ 68 M
Market Cap
-0.43
P/E
CASH FLOW STATEMENT
-130 M
OPERATING CASH FLOW
44.7 M
INVESTING CASH FLOW
59.3 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ALX Oncology Holdings Inc.
| Net Income | -161 M |
| Depreciation & Amortization | 836 K |
| Capital Expenditures | -1.27 M |
| Stock-Based Compensation | 26.3 M |
| Change in Working Capital | 8.3 M |
| Others | 2.87 M |
| Free Cash Flow | -132 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (160.8) | (123.5) | (83.5) | (45.7) | (19.2) | (13.7) |
| Depreciation & Amortization | 0.8 | 0.3 | 51 K | 0.2 | 0.4 | 0.4 |
| Deferred Income Tax | 0 | 0 | 0 | 1.3 | 0 | 0 |
| Stock Based Compensation | 26.3 | 23.8 | 13.9 | 5.4 | 0.3 | 0.3 |
| Other Operating Activities | (5.0) | 0.2 | 5.4 | 0.3 | 11 K | 2.3 |
| Change in Working Capital | 8.3 | 9.8 | (4.0) | 0.2 | 4.3 | (0.2) |
| Cash From Operations | (130.4) | (89.2) | (68.1) | (38.3) | (14.2) | (13.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.3) | (1.4) | (4.9) | 31 K | (0.4) | (0.7) |
| Other Items | 45.9 | (234.0) | 0 | 0.6 | 0 | 0 |
| Cash From Investing Activities | 44.7 | (235.4) | (4.9) | 0.6 | (0.4) | (0.7) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0.3 | 0.2 | 0 | 0 | 6 K |
| Total Debt Repaid | (0.4) | 9.6 | (0.3) | (6.5) | 5.9 | 0 |
| Dividends Paid | 0 | 0 | 0 | 3 K | 0 | 0 |
| Other Financing Activities | 0.8 | 0.2 | 2.8 | 104.7 | 9.4 | 7 K |
| Cash From Financing Activities | 59.3 | 9.9 | 2.5 | 462.9 | 15.4 | 1 K |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (26.4) | (314.8) | (70.6) | 425.2 | 0.8 | (13.8) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (131.6) | (90.7) | (73.0) | (38.3) | (14.6) | (13.8) |